Recent news regarding pharma companies in Asia
An IPO for raising USD 115 million from public investors has been filed by Translate Bio. Proceeds garnered from the IPO will be used by Translate to trial an mRNA candidate designed to allow cystic fibrosis patients produce CTFR proteins.
The team is focusing to make Alex, the voice assistant, more convenient and useful in the health-care sector, which requires regulations and data privacy set by the HIPAA – Health Insurance Portability and Accountability Act. The experts are aiming to work on diabetes management, assistance for mother, infants and the elderly.
Aseptika in St Ives and Zenzium in Cheshire have been awarded an unspecified grant from the UK’s innovation agency to leverage AI and develop a new home-based early warning system for people with severe respiratory disease.
Four health systems — Intermountain Healthcare, Ascension, SSM Health and Trinity Health — and the U.S. Department of Veterans Affairs will launch a nonprofit generic drug company.
Rani Therapeutics scored $53 million in financing to take its oral pill designed to replace injectable drug delivery for chronic disease treatment into clinical trials.
Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, today announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials. This investment brings the total raised to $142 million in funding.
Amazon and two other American titans are trying to shake up health care by experimenting with their own employees’ coverage. By Chinese standards, they’re behind the curve.
Hospitals and healthcare providers remain under cyber attack, causing organizations to spend more to protect their systems and patient data.
Food allergy has been referred to as the second wave of the allergy epidemic, asthma being the first.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.